CYTK

Recent stories

• +8

  Cytokinetics initiates study for symptomatic obstructive cardiomyopathy.

  1 source·30/09, 11:42·finviz.com

• +9

  FDA approves MYQORZO for obstructive hypertrophic cardiomyopathy.

  1 source·19/12, 21:02·sec.gov

• +8

  Positive opinion for MYQORZO® marketing authorization.

  1 source·12/12, 13:56·sec.gov

• +3

  Cytokinetics appoints new Chief Legal and Administrative Officer.

  1 source·14/11, 21:10·sec.gov

• 0

  10-Q form submitted!

  1 source·05/11, 21:32·sec.gov

• 0

  Cytokinetics announces third quarter financial results.

  1 source·05/11, 21:10·sec.gov

• +7

  Cytokinetics issued $750 million in convertible senior notes.

  1 source·22/09, 10:04·sec.gov

• +8

  FDA meeting suggests positive trajectory for aficamten approval.

  1 source·16/09, 20:10·sec.gov

• +7

  Positive data on aficamten presented at ESC Congress.

  1 source·08/09, 21:04·sec.gov

• +8

  Aficamten data presented at cardiology congress.

  1 source·03/09, 10:02·sec.gov